Shattuck Labs, Inc.
STTK- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001680367
No open-market purchases or sales by Shattuck Labs, Inc. insiders were filed in the last 90 days; 100 institutions reported holding it in 13F filings for Q2 2026, worth $581.3M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 12, 2026
- $489.9M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +17 vs. previous quarter
- 100
- 13F valueReported value at the end of Q2 2026
- $581.3M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $1.00M
- −82.5% year over year
- Net income, FY2025
- -$48.8M
- No comparable prior period
- Free cash flow, FY2025
- -$40.0M
- No comparable prior period
- Revenue, Q3 FY2026
- $0
- −100.0% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $48.8M (4880.9% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 10.7M
- Shares sold short
- Change
- +305.4K
- +2.9% vs. previous
- Days to cover
- 11.97
- At average daily volume
Superinvestors holding STTK, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding STTK at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Shattuck Labs, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 7, 2026 (view filing)7:00 PM ET | Jul 2 | 5 days | Shukla Abhinav A.Chief Technical Officer | SSale | −410 | $7.01 | −$2.87K | −0.5%86.4K after | 10b5-1 |
| Jul 2, 2026 (view filing)8:17 PM ET | Jun 30-Jul 1 | 2 days | Shukla Abhinav A.Chief Technical Officer | SSale | −23.5K | $7.08 | −$166.1K | −21.4%86.4K after | 2 lots10b5-1 |
| Jul 2, 2026 (view filing)8:15 PM ET | Jun 30 | 2 days | Pandite Arundathy N.Chief Medical Officer | SSale | −30.0K | $7.01 | −$210.3K | −18.0%136.2K after | 10b5-1 |
| Jun 15, 2026 (view filing)6:12 PM ET | Jun 11 | 4 days | OrbiMed Advisors LLC and 2 othersDirector | PPurchase | +1.25M | – | – | –5.30M after | Derivative2 lotsDuplicate filing |
| Jun 15, 2026 (view filing) | Jun 11 | 4 days | Ashiya MonaDirector | PPurchase | +1.25M | – | – | –5.30M after | Derivative2 lots |
| Jun 11, 2026 (view filing) | Jun 9 | 2 days | Siegall Clay BDirector | PPurchase | +62.5K | $4.00 | +$250.0K | +24.4%318.6K after | |
| May 14, 2026 (view filing) | May 12 | 2 days | Shukla Abhinav A.Chief Technical Officer | SSale | −2.03K | $7.01 | −$14.2K | −2.4%81.3K after | 10b5-1 |
| May 14, 2026 (view filing) | May 12 | 2 days | Pandite Arundathy N.Chief Medical Officer | SSale | −30.0K | $6.61 | −$198.3K | −15.3%166.2K after | 10b5-1 |
| Sep 2, 2025 (view filing)9:52 PM ET | Aug 25 | 8 daysLate | OrbiMed Advisors LLC and 2 othersDirector | PPurchase | +6.31M | $0.8677 | +$5.47M | New position1.05M after | 2 lots |
| Sep 2, 2025 (view filing)9:52 PM ET | Aug 25 | 8 daysLate | OrbiMed Advisors LLC and 2 othersDirector | PPurchase | +30.6M | – | – | –3.07M after | Derivative4 lotsDuplicate filing |
Top 10 13F holders, Q2 2026
See all 100 holdersThe largest institutional positions in Shattuck Labs, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 13,432,540 | $93.2M | 0.06% | +3,566,982+36.2% | Added |
| Adage Capital Partners GP, L.L.C. | 8,122,179 | $56.4M | 0.08% | +3,477,222+74.9% | Added |
| Redmile Group, LLC | 6,892,033 | $47.8M | 3.21% | +1,352,309+24.4% | Added |
| OrbiMed Advisors LLC | 6,306,127 | $43.8M | 0.83% | 00.0% | Unchanged |
| Prosight Management, LP | 5,957,877 | $41.3M | 7.12% | +953,438+19.1% | Added |
| BlackRock, Inc. | 3,935,810 | $27.3M | 0.00% | +3,425,004+670.5% | Added |
| Frazier Life Sciences Management, L.P. | 3,750,000 | $26.0M | 0.57% | +3,750,000 | New |
| NEXTBio Capital Management LP | 3,727,348 | $25.9M | 11.90% | +577,441+18.3% | Added |
| Deep Track Capital, LP | 3,706,734 | $25.7M | 0.38% | +3,706,734 | New |
| Vanguard Capital Management LLC | 3,207,865 | $22.3M | 0.00% | +930,689+40.9% | Added |
Holders of 5% or more of STTK
See all 7 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Shattuck Labs, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 13G/A | 15.30%13.4M shares | +1.50 ppfrom 13.80% | Feb 6, 20263 filings | Aug 14, 2026 | SEC |
| OrbiMed Advisors LLC | 13D/A | 9.99%9.02M shares | 0.00 ppfrom 9.99% | Sep 2, 20252 filings | Jun 15, 2026 | SEC |
| Redmile Group, LLC | 13D/A | 9.90%10.0M shares | 0.00 ppfrom 9.90% | Dec 26, 20236 filings | Jul 17, 2026 | SEC |
| Prosight Management, LP | 13G/A | 9.90%6.54M shares | – | Jan 2, 20244 filings | Nov 13, 2025 | SEC |
| Adage Capital Partners GP, L.L.C. | 13G/A | 9.79%4.67M shares | – | Jan 29, 20242 filings | Feb 12, 2025 | SEC |